Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive has a strong emphasis on technology adoption, utilizing various tools to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Tiziana Life Sciences is advancing its investigational drug, intranasal foralumab, for moderate Alzheimer's disease, which currently lacks effective treatment options, as highlighted in a recent news segment featuring a patient from the company's expanded access program [1][2]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly intranasal administration [8][9]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [9]. Drug Mechanism and Efficacy - Foralumab targets immune system dysregulation associated with Alzheimer's disease, potentially slowing disease progression and improving cognitive function by modulating inflammation linked to neurodegeneration [3][5]. - The drug has shown efficacy in reducing microglial activation and inducing T regulatory cells, which help modulate neuroinflammation, validated in animal models and patients with secondary progressive multiple sclerosis [5][7]. Expanded Access Program - The expanded access program allows patients without access to clinical trials to receive intranasal foralumab as part of a compassionate use initiative, with initial results showing improvement or stability in disease for all 10 patients dosed [6]. Clinical Trials - Tiziana is conducting a Phase 2a, randomized, double-blind, placebo-controlled trial for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis, which began screening patients in November 2023 [7][6].

Core Viewpoint - Tiziana Life Sciences is advancing intranasal foralumab as a promising therapy for moderate Alzheimer's disease, which currently lacks effective treatment options [2][4]. Company Overview - Tiziana Life Sciences, Ltd. is a biotechnology company focused on developing innovative immunomodulation therapies, with intranasal foralumab as its lead candidate [2][10]. - The company utilizes a novel nasal delivery method for its therapies, which may enhance efficacy and safety compared to traditional intravenous methods [10]. Product Development - Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce inflammation associated with neurodegenerative diseases [4][6]. - The drug has shown efficacy in reducing microglial activation and improving cognitive function in preclinical and clinical settings [6][9]. - An expanded access program has been initiated, allowing patients with moderate Alzheimer's to receive treatment outside of clinical trials [4][8]. Clinical Insights - The first patient in the expanded access program shared positive experiences, highlighting the potential benefits of foralumab for individuals with moderate Alzheimer's [2][3]. - The drug has demonstrated a favorable safety profile and clinical response in patients with non-active secondary progressive multiple sclerosis (na-SPMS) [8][10]. - The FDA has approved the enrollment of an additional 20 patients in the expanded access program, indicating growing interest and confidence in the therapy [8]. Mechanism of Action - Foralumab works by inducing T regulatory cells (Tregs) that travel to the brain, modulating neuroinflammation and potentially slowing disease progression [4][6]. - The therapy targets immune system dysregulation, which is a critical factor in the pathogenesis of Alzheimer's disease [4][5]. Market Context - The increasing recognition of microglial activation as a key component in neurodegenerative diseases underscores the need for treatments that go beyond traditional amyloid-targeting therapies [5][7]. - Tiziana's innovative approach positions it favorably within the competitive landscape of Alzheimer's and neurodegenerative disease therapies [10].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Tiziana Life Sciences is advancing its intranasal foralumab, a fully human anti-CD3 monoclonal antibody, showing promising results in treating traumatic spinal cord injury (SCI) through modulation of microglial inflammation [1][4][5]. Group 1: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly intranasal routes for immunotherapy [8]. - The lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [8]. Group 2: Research Findings - Preclinical studies indicate that treatment with nasal anti-CD3 significantly improves motor functions in models of spinal cord injury by dampening microglial activation [2][5]. - Approximately 300,000 individuals in the U.S. are living with spinal cord injuries, with over 17,000 new cases reported annually, highlighting the urgent need for effective treatments [3]. Group 3: Scientific Insights - The inflammatory response mediated by microglia is crucial in the pathogenesis of spinal cord injuries, and nasal anti-CD3 plays a pivotal role in modulating this inflammation [2][4]. - Foralumab stimulates T regulatory cells when administered intranasally, which may lead to reduced inflammation and improved outcomes in neuroinflammatory conditions [6][7].

Core Insights - Tiziana Life Sciences has announced its intention not to engage in capital raising activities for the immediate future, following the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab [1][2] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, particularly through nasal administration [3] - The lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [3] - The company's nasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [3] Commitment to Shareholders - The management team of Tiziana Life Sciences remains dedicated to delivering value to shareholders while advancing its innovative drug candidates through clinical trials and regulatory processes [2]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially t ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation. This advan ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...